Biomea Fusion (NASDAQ:BMEA - Get Free Report) posted its earnings results on Monday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.19, Zacks reports.
Biomea Fusion Stock Performance
NASDAQ BMEA traded down $0.21 during trading hours on Thursday, reaching $1.95. The stock had a trading volume of 663,139 shares, compared to its average volume of 915,669. Biomea Fusion has a 52-week low of $1.87 and a 52-week high of $14.43. The stock has a fifty day moving average of $3.19 and a 200 day moving average of $5.89. The stock has a market cap of $70.67 million, a P/E ratio of -0.49 and a beta of -0.26.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on the stock. Barclays cut their price objective on shares of Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Wednesday. D. Boral Capital reaffirmed a "buy" rating and issued a $16.00 price target on shares of Biomea Fusion in a report on Wednesday, March 19th. Oppenheimer set a $10.00 price objective on Biomea Fusion in a report on Monday, March 24th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Biomea Fusion in a research report on Monday. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Biomea Fusion presently has an average rating of "Buy" and a consensus price target of $23.91.
View Our Latest Report on BMEA
Biomea Fusion Company Profile
(
Get Free Report)
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
Read More
Before you consider Biomea Fusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biomea Fusion wasn't on the list.
While Biomea Fusion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
